222 related articles for article (PubMed ID: 35125081)
1. An Insight into the Molecular Mechanism of Mitochondrial Toxicant-induced Neuronal Apoptosis in Parkinson's Disease.
Brahadeeswaran S; Lateef M; Calivarathan L
Curr Mol Med; 2023; 23(1):63-75. PubMed ID: 35125081
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial Toxicant-Induced Neuronal Apoptosis in Parkinson's Disease: What We Know so Far.
Sivagurunathan N; Gnanasekaran P; Calivarathan L
Degener Neurol Neuromuscul Dis; 2023; 13():1-13. PubMed ID: 36726995
[TBL] [Abstract][Full Text] [Related]
3. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial dysfunction and oxidative stress in Parkinson's disease.
Subramaniam SR; Chesselet MF
Prog Neurobiol; 2013; 106-107():17-32. PubMed ID: 23643800
[TBL] [Abstract][Full Text] [Related]
5. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
Hattori N
Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
[TBL] [Abstract][Full Text] [Related]
6. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.
Banerjee R; Starkov AA; Beal MF; Thomas B
Biochim Biophys Acta; 2009 Jul; 1792(7):651-63. PubMed ID: 19059336
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
9. The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.
Olesen MA; Villavicencio-Tejo F; Quintanilla RA
Transl Neurodegener; 2022 Jul; 11(1):36. PubMed ID: 35787292
[TBL] [Abstract][Full Text] [Related]
10. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial dysfunctions in Parkinson's disease.
Gautier CA; Corti O; Brice A
Rev Neurol (Paris); 2014 May; 170(5):339-43. PubMed ID: 24119854
[TBL] [Abstract][Full Text] [Related]
12. Current perspective of mitochondrial biology in Parkinson's disease.
Ammal Kaidery N; Thomas B
Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
[TBL] [Abstract][Full Text] [Related]
13. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
15. Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage.
Flønes IH; Fernandez-Vizarra E; Lykouri M; Brakedal B; Skeie GO; Miletic H; Lilleng PK; Alves G; Tysnes OB; Haugarvoll K; Dölle C; Zeviani M; Tzoulis C
Acta Neuropathol; 2018 Mar; 135(3):409-425. PubMed ID: 29270838
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in Parkinson's disease (recent update).
Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
[TBL] [Abstract][Full Text] [Related]
18. IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson's disease.
Kim H; Kim SH; Cha H; Kim SR; Lee JH; Park JW
Free Radic Res; 2016 Aug; 50(8):853-60. PubMed ID: 27142242
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial pathobiology in Parkinson's disease and amyotrophic lateral sclerosis.
Martin LJ
J Alzheimers Dis; 2010; 20 Suppl 2():S335-56. PubMed ID: 20413846
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
